Universität zu Köln

Schmidt, Nina, Dressel, Alexander, Grammer, Tanja B., Gouni-Berthold, Ioanna, Julius, Ulrich, Kassner, Ursula, Klose, Gerald, Koenig, Christel, Koenig, Wolfgang, Otte, Britta, Parhofer, Klaus G., Reinhard, Wibke, Schatz, Ulrike, Schunkert, Heribert, Steinhagen-Thiessen, Elisabeth, Vogt, Anja, Laufs, Ulrich and Maerz, Winfried (2018). Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis, 277. S. 314 - 323. CLARE: ELSEVIER IRELAND LTD. ISSN 1879-1484

Full text not available from this repository.

Abstract

Background and aims: Familial hypercholesterolemia (FH) is amongst the most common genetic disorders encountered in primary care. Yet, only a minority of affected patients is diagnosed and treated. This interim analysis of the CaRe High Registry aims at examining the state of treatment and attainment of lipid goals in German FH patients. Methods: The CaRe High registry includes FH patients from lipid clinics and private practices. Data have been collected using questionnaires filled in by the recruiting physicians and by interviewing the participating patients. Results: We examined 512 F H patients diagnosed according to clinical criteria. Median age at the time of the first FH diagnosis was 39 (25th and 75th percentile: 27-50) years, median treatment naive LDL cholesterol (LDLC) was 239.4 mg/dl (6.19 mmol/l), 25th to 75th percentile 191.8-342.5 mg/dl (4.96-8.86 mmol/l). 27% of the participants did not receive lipid-lowering drugs. Among the patients treated with lipid-lowering drugs, 19% received a PCSK9 inhibitor (PCSK9i) in combination with a statin, 9% were treated with a PCSK9i alone and 3% were treated with a combination of PCSK9i and a non-statin drug. Patients with pre-existing CVD were more likely to be treated with lipid-lowering drugs and more likely to receive a PCSK9i, but LDL-C targets were only achieved by a minority of patients (<20%). Gap to target LDL-C was lowest and the median achieved LDL-C reduction was 1.4 times higher with PCSK9i treatment than with (oral) lipid-lowering therapy without PCSK9i. Conclusions: The Care High registry has included patients with the typical clinical features of familial hypercholesterolemia. PCSK9i treatment in addition to standard therapy allows attainment of target values in many patients with initially very high LDL-C.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schmidt, Nina UNSPECIFIED UNSPECIFIED UNSPECIFIED Dressel, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Grammer, Tanja B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gouni-Berthold, Ioanna UNSPECIFIED UNSPECIFIED UNSPECIFIED Julius, Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Kassner, Ursula UNSPECIFIED UNSPECIFIED UNSPECIFIED Klose, Gerald UNSPECIFIED UNSPECIFIED UNSPECIFIED Koenig, Christel UNSPECIFIED UNSPECIFIED UNSPECIFIED Koenig, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Otte, Britta UNSPECIFIED UNSPECIFIED UNSPECIFIED Parhofer, Klaus G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reinhard, Wibke UNSPECIFIED UNSPECIFIED UNSPECIFIED Schatz, Ulrike UNSPECIFIED UNSPECIFIED UNSPECIFIED Schunkert, Heribert UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinhagen-Thiessen, Elisabeth UNSPECIFIED UNSPECIFIED UNSPECIFIED Vogt, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Laufs, Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Maerz, Winfried UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-171567
DOI:	10.1016/j.atherosclerosis.2018.08.050
Journal or Publication Title:	Atherosclerosis
Volume:	277
Page Range:	S. 314 - 323
Date:	2018
Publisher:	ELSEVIER IRELAND LTD
Place of Publication:	CLARE
ISSN:	1879-1484
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ASSOCIATION EXPERT PANEL; GENE; MUTATIONS; DIAGNOSIS; RECEPTOR; MANAGEMENT Multiple languages Cardiac & Cardiovascular Systems; Peripheral Vascular Disease Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/17156